How Stanozolol Affects LDL Cholesterol

Stanozolol raises LDL through the hepatic consequences of its 17-alpha-alkylated structure, which are the mirror image of what it does to HDL:

1. First-pass hepatic loading: The 17-alpha-alkyl group exists to let the molecule survive first-pass metabolism. The cost is that hepatocytes are exposed to a concentrated androgen bolus after every dose. This is the mechanistic difference Thompson (1989, PMID 2915439) set out to test, and the result was unambiguous: route of administration, not androgenic potency, drove the lipid damage.

2. Downregulation of hepatic LDL receptor activity: Androgenic signalling at the hepatocyte reduces LDL receptor expression, slowing clearance of LDL particles from plasma. Fewer receptors means LDL particles circulate for longer, and plasma LDL cholesterol rises.

3. No oestrogenic counterbalance: Stanozolol does not aromatise. Oestradiol is the hormone that upregulates hepatic LDL receptors, so a non-aromatising oral removes the one androgen-associated mechanism that supports LDL clearance. Zmuda (1993, PMID 8487666) showed that removing oestradiol from a testosterone protocol worsened lipids; stanozolol never had it in the first place.

4. Simultaneous HTGL surge: Applebaum-Bowden (1987, PMID 3657514) documented hepatic triglyceride lipase activity rising 230% within three days of starting stanozolol. HTGL drives HDL down while the receptor changes push LDL up, which is why the LDL to HDL ratio deteriorates far faster than either marker alone suggests.

The net result is that stanozolol moves both sides of the ratio in the wrong direction at once, which no injectable androgen does to the same degree.

At 6 mg/day (Thompson 1989, PMID 2915439, six weeks, randomised crossover in 11 male weightlifters):

• LDL cholesterol: +29%
• HDL cholesterol: -33%
• HDL2 subfraction: -71%
• Apolipoprotein A-I: -40%
• Hepatic triglyceride lipase activity: +123%
• The same men on 200 mg/week intramuscular testosterone enanthate saw LDL fall 16%.

At bodybuilding doses (25-50 mg/day):

• No controlled trial has measured LDL at these doses. The 29% figure comes from 6 mg/day, four to eight times lower than typical use.
• Glazer (1991, PMID 1929679) pooled the anabolic steroid lipid literature and reported a weighted average LDL rise of 36% across compounds and doses. That is the most defensible number to hold in mind for a stanozolol cycle, and it may still understate a 50 mg/day protocol.
• An LDL to HDL ratio of 6 or higher is realistic on a stanozolol cycle. Webb (1984, PMID 6493049) measured 6.0 in bodybuilders on oral-containing stacks versus 2.2 off.

Timing: HTGL surges within 72 hours. LDL moves more slowly than HDL, typically becoming measurable by week 2 to 3 and reaching its plateau by week 4 to 6.

Recovery: Reversible. Thompson's subjects were studied over six-week blocks with washout, and lipid changes resolved. Expect 4 to 12 weeks for LDL to return toward baseline after stopping.

Baseline is mandatory: A pre-cycle lipid panel including LDL, HDL, total cholesterol and, if available, ApoB. Without a baseline you cannot tell a 29% rise from a normal reading.

On cycle:

• Check lipids at week 3 to 4. This is the window in which the change is established.
• Look at the LDL to HDL ratio, not LDL alone. Stanozolol moves both, so the ratio deteriorates roughly twice as fast as either number.
• ApoB is the better call than LDL cholesterol if you can only afford one addition to the panel.

Thresholds worth acting on:

• LDL above 4.9 mmol/L (190 mg/dL) is the conventional threshold for pharmacological treatment in the general population, and reaching it on a 4-week oral cycle is a strong argument to stop the compound.
• An LDL to HDL ratio above 5 represents a lipid profile that is difficult to justify for a cosmetic cycle.

Post-cycle: Recheck at 4 and 8 weeks after stopping to confirm the reversal is happening.

The intervention that works is stopping the compound:

• No supplement offsets a 29% LDL rise plus a 33% HDL fall. Keeping the cycle short, 4 to 6 weeks maximum, limits cumulative arterial exposure and is the only genuinely effective lever.

During the cycle:

• Do not stack a second oral. The effects are additive on both the lipid and the hepatic side.
• Cardiovascular exercise: 30 to 45 minutes, 4 to 5 times per week. This is the highest-evidence non-drug intervention available.
• Soluble fibre: 10 to 25 g/day (psyllium, oats, legumes) modestly lowers LDL through bile acid sequestration, an entirely separate pathway from the one stanozolol is disrupting.
• Omega-3 fatty acids: 3 to 4 g/day EPA and DHA. Effective for triglycerides, minimal effect on LDL. Do not expect it to fix the LDL number.
• Citrus bergamot: 500 to 1000 mg/day has some human evidence for LDL reduction, though not in androgen users. Treat it as a small adjunct, not a solution.

If you are already on a statin: Continue it. There is no interaction that argues for stopping lipid-lowering therapy during an oral cycle, and the case for it is stronger, not weaker.

Further reading: Cholesterol supplements on cycle, ranked by evidence